

# Joseph G Ibrahim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8343735/publications.pdf>

Version: 2024-02-01

292  
papers

15,950  
citations

26567

56  
h-index

21474

114  
g-index

297  
all docs

297  
docs citations

297  
times ranked

13549  
citing authors

#	ARTICLE	IF	CITATIONS
1	High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801. <i>Journal of Clinical Oncology</i> , 2001, 19, 2370-2380.	0.8	907
2	High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190. <i>Journal of Clinical Oncology</i> , 2000, 18, 2444-2458.	0.8	900
3	Bayesian Survival Analysis. <i>Springer Series in Statistics</i> , 2001, , .	0.9	634
4	Monte Carlo Methods in Bayesian Computation. <i>Springer Series in Statistics</i> , 2000, , .	0.9	556
5	A Pooled Analysis of Eastern Cooperative Oncology Group and Intergroup Trials of Adjuvant High-Dose Interferon for Melanoma. <i>Clinical Cancer Research</i> , 2004, 10, 1670-1677.	3.2	510
6	Power prior distributions for regression models. <i>Statistical Science</i> , 2000, 15, 46.	1.6	459
7	UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Dose Matters. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1290-1295.	3.0	436
8	Expression of $p16^{INK4a}$ in peripheral blood T cells is a biomarker of human aging. <i>Aging Cell</i> , 2009, 8, 439-448.	3.0	381
9	A New Bayesian Model for Survival Data with a Surviving Fraction. <i>Journal of the American Statistical Association</i> , 1999, 94, 909-919.	1.8	365
10	Missing-Data Methods for Generalized Linear Models. <i>Journal of the American Statistical Association</i> , 2005, 100, 332-346.	1.8	363
11	Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group Trials. <i>Journal of Clinical Oncology</i> , 2000, 18, 3782-3793.	0.8	340
12	Missing data methods in longitudinal studies: a review. <i>Test</i> , 2009, 18, 1-43.	0.7	340
13	Use of historical control data for assessing treatment effects in clinical trials. <i>Pharmaceutical Statistics</i> , 2014, 13, 41-54.	0.7	340
14	Basic Concepts and Methods for Joint Models of Longitudinal and Survival Data. <i>Journal of Clinical Oncology</i> , 2010, 28, 2796-2801.	0.8	298
15	Incomplete Data in Generalized Linear Models. <i>Journal of the American Statistical Association</i> , 1990, 85, 765-769.	1.8	248
16	Effect of Cytotoxic Chemotherapy on Markers of Molecular Age in Patients With Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju057.	3.0	218
17	INK4/ARF Transcript Expression Is Associated with Chromosome 9p21 Variants Linked to Atherosclerosis. <i>PLoS ONE</i> , 2009, 4, e5027.	1.1	217
18	The power prior: theory and applications. <i>Statistics in Medicine</i> , 2015, 34, 3724-3749.	0.8	178

#	ARTICLE	IF	CITATIONS
19	Genotype-Guided Tamoxifen Dosing Increases Active Metabolite Exposure in Women With Reduced CYP2D6 Metabolism: A Multicenter Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 3232-3239.	0.8	173
20	A Bayesian Semiparametric Joint Hierarchical Model for Longitudinal and Survival Data. <i>Biometrics</i> , 2003, 59, 221-228.	0.8	154
21	Missing Data in Clinical Studies: Issues and Methods. <i>Journal of Clinical Oncology</i> , 2012, 30, 3297-3303.	0.8	145
22	A Flexible B-Spline Model for Multiple Longitudinal Biomarkers and Survival. <i>Biometrics</i> , 2005, 61, 64-73.	0.8	140
23	High-Dose Interferon Alfa-2b Does Not Diminish Antibody Response to GM2 Vaccination in Patients With Resected Melanoma: Results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. <i>Journal of Clinical Oncology</i> , 2001, 19, 1430-1436.	0.8	135
24	Bayesian Models for Gene Expression With DNA Microarray Data. <i>Journal of the American Statistical Association</i> , 2002, 97, 88-99.	1.8	133
25	Cure rate models: A unified approach. <i>Canadian Journal of Statistics</i> , 2005, 33, 559-570.	0.6	125
26	Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced challenge with open clinical trial data. <i>Lancet Oncology</i> , The, 2017, 18, 132-142.	5.1	124
27	Joint Models for Multivariate Longitudinal and Multivariate Survival Data. <i>Biometrics</i> , 2006, 62, 432-445.	0.8	123
28	In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3. <i>Drug Metabolism and Disposition</i> , 2010, 38, 25-31.	1.7	115
29	On Bayesian Analysis of Generalized Linear Models Using Jeffreys's Prior. <i>Journal of the American Statistical Association</i> , 1991, 86, 981-986.	1.8	111
30	Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group. <i>Statistics in Medicine</i> , 2015, 34, 2181-2195.	0.8	104
31	A conditional model for incomplete covariates in parametric regression models. <i>Biometrika</i> , 1996, 83, 916-922.	1.3	103
32	Fixed and Random Effects Selection in Mixed Effects Models. <i>Biometrics</i> , 2011, 67, 495-503.	0.8	103
33	Monte Carlo EM for Missing Covariates in Parametric Regression Models. <i>Biometrics</i> , 1999, 55, 591-596.	0.8	102
34	Semiparametric Transformation Models for Survival Data With a Cure Fraction. <i>Journal of the American Statistical Association</i> , 2006, 101, 670-684.	1.8	101
35	Large-scale GWAS reveals genetic architecture of brain white matter microstructure and genetic overlap with cognitive and mental health traits (n=17,706). <i>Molecular Psychiatry</i> , 2021, 26, 3943-3955.	4.1	100
36	REC, Drosophila MCM8, Drives Formation of Meiotic Crossovers. <i>PLoS Genetics</i> , 2005, 1, e40.	1.5	97

#	ARTICLE	IF	CITATIONS
37	Model Selection Criteria for Missing-Data Problems Using the EM Algorithm. Journal of the American Statistical Association, 2008, 103, 1648-1658.	1.8	93
38	Immunomodulatory effects of high-dose and low-dose interferon $\gamma$ in patients with high-risk resected melanoma. Cancer, 2002, 95, 1101-1112.	2.0	92
39	Bayesian methods for generalized linear models with covariates missing at random. Canadian Journal of Statistics, 2002, 30, 55-78.	0.6	89
40	A Weighted Estimating Equation for Missing Covariate Data with Properties Similar to Maximum Likelihood. Journal of the American Statistical Association, 1999, 94, 1147-1160.	1.8	88
41	Bayesian Semiparametric Models for Survival Data with a Cure Fraction. Biometrics, 2001, 57, 383-388.	0.8	86
42	Parameter Estimation in Longitudinal Studies with Outcome-Dependent Follow-Up. Biometrics, 2002, 58, 621-630.	0.8	80
43	Perturbation selection and influence measures in local influence analysis. Annals of Statistics, 2007, 35, .	1.4	79
44	Maximum Likelihood Methods for Cure Rate Models with Missing Covariates. Biometrics, 2001, 57, 43-52.	0.8	77
45	A Predictive Approach to the Analysis of Designed Experiments. Journal of the American Statistical Association, 1994, 89, 309-319.	1.8	75
46	A semi-parametric Bayesian approach to generalized linear mixed models. , 1998, 17, 2579-2596.		74
47	The relationship between the power prior and hierarchical models. Bayesian Analysis, 2006, 1, 551.	1.6	74
48	Bayesian Approaches to Joint Cure-Rate and Longitudinal Models with Applications to Cancer Vaccine Trials. Biometrics, 2003, 59, 686-693.	0.8	72
49	Likelihood-Based Methods for Missing Covariates in the Cox Proportional Hazards Model. Journal of the American Statistical Association, 2001, 96, 292-302.	1.8	71
50	Bayesian Inference for Multivariate Survival Data with a Cure Fraction. Journal of Multivariate Analysis, 2002, 80, 101-126.	0.5	71
51	The treatment and outcome of cancer patients with thromboses on central venous catheters. Journal of Thrombosis and Thrombolysis, 2000, 10, 271-275.	1.0	68
52	On Optimality Properties of the Power Prior. Journal of the American Statistical Association, 2003, 98, 204-213.	1.8	67
53	Bayesian Model Averaging With Applications to Benchmark Dose Estimation for Arsenic in Drinking Water. Journal of the American Statistical Association, 2006, 101, 9-17.	1.8	67
54	Genomewide Multiple-Loci Mapping in Experimental Crosses by Iterative Adaptive Penalized Regression. Genetics, 2010, 185, 349-359.	1.2	67

#	ARTICLE	IF	CITATIONS
55	Power prior distributions for generalized linear models. Journal of Statistical Planning and Inference, 2000, 84, 121-137.	0.4	65
56	Maximum Likelihood Methods for Nonignorable Missing Responses and Covariates in Random Effects Models. Biometrics, 2003, 59, 1140-1150.	0.8	63
57	Use of the Probability Integral Transformation to Fit Nonlinear Mixed-Effects Models With Nonnormal Random Effects. Journal of Computational and Graphical Statistics, 2006, 15, 39-57.	0.9	60
58	Statistical Analysis of Diffusion Tensors in Diffusion-Weighted Magnetic Resonance Imaging Data. Journal of the American Statistical Association, 2007, 102, 1085-1102.	1.8	60
59	Bayesian Design of Noninferiority Trials for Medical Devices Using Historical Data. Biometrics, 2011, 67, 1163-1170.	0.8	60
60	Bayesian Generalized Low Rank Regression Models for Neuroimaging Phenotypes and Genetic Markers. Journal of the American Statistical Association, 2014, 109, 977-990.	1.8	59
61	Using Historical Controls to Adjust for Covariates in Trend Tests for Binary Data. Journal of the American Statistical Association, 1998, 93, 1282-1293.	1.8	56
62	GEE with Gaussian Estimation of the Correlations When Data Are Incomplete. Biometrics, 2000, 56, 528-536.	0.8	56
63	Bayesian clinical trial design using historical data that inform the treatment effect. Biostatistics, 2019, 20, 400-415.	0.9	56
64	Defective Cell Cycle Checkpoint Functions in Melanoma Are Associated with Altered Patterns of Gene Expression. Journal of Investigative Dermatology, 2008, 128, 175-187.	0.3	55
65	Post-diagnosis physical activity and survival after breast cancer diagnosis: the Long Island Breast Cancer Study. Breast Cancer Research and Treatment, 2014, 145, 735-742.	1.1	55
66	Nonparametric expression analysis using inferential replicate counts. Nucleic Acids Research, 2019, 47, e105-e105.	6.5	54
67	Bayesian variable selection for proportional hazards models. Canadian Journal of Statistics, 1999, 27, 701-717.	0.6	51
68	Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome. Journal of Clinical Oncology, 1999, 17, 1175-1175.	0.8	50
69	An Estimate of the Odds Ratio That Always Exists. Journal of Computational and Graphical Statistics, 2002, 11, 420-436.	0.9	50
70	$\omega$ 3 Fatty acids, hypertension and risk of cognitive decline among older adults in the Atherosclerosis Risk in Communities (ARIC) study. Public Health Nutrition, 2008, 11, 17-29.	1.1	50
71	Parameter Estimation from Incomplete Data in Binomial Regression When the Missing Data Mechanism is Nonignorable. Biometrics, 1996, 52, 1071.	0.8	49
72	Estimating Equations with Incomplete Categorical Covariates in the Cox Model. Biometrics, 1998, 54, 1002.	0.8	48

#	ARTICLE	IF	CITATIONS
73	A Note on Permutation Tests for Variance Components in Multilevel Generalized Linear Mixed Models. <i>Biometrics</i> , 2007, 63, 942-946.	0.8	48
74	Sample size and power determination in joint modeling of longitudinal and survival data. <i>Statistics in Medicine</i> , 2011, 30, 2295-2309.	0.8	48
75	A New Bayesian Model for Survival Data with a Surviving Fraction. , 0, .		48
76	Structured Measurement Error in Nutritional Epidemiology. <i>Journal of the American Statistical Association</i> , 2007, 102, 856-866.	1.8	45
77	Using auxiliary data for parameter estimation with non-ignorable missing outcomes. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 361-373.	0.5	44
78	Bayesian Case Influence Diagnostics for Survival Models. <i>Biometrics</i> , 2009, 65, 116-124.	0.8	44
79	Intrinsic Regression Models for Positive-Definite Matrices With Applications to Diffusion Tensor Imaging. <i>Journal of the American Statistical Association</i> , 2009, 104, 1203-1212.	1.8	44
80	The effects of nonignorable missing data on label-free mass spectrometry proteomics experiments. <i>Annals of Applied Statistics</i> , 2018, 12, 2075-2095.	0.5	44
81	Regression Models for Identifying Noise Sources in Magnetic Resonance Images. <i>Journal of the American Statistical Association</i> , 2009, 104, 623-637.	1.8	43
82	Pathologic and gene expression features of metastatic melanomas to the brain. <i>Cancer</i> , 2013, 119, 2737-2746.	2.0	42
83	Tamoxifen Dose Escalation in Patients With Diminished CYP2D6 Activity Normalizes Endoxifen Concentrations Without Increasing Toxicity. <i>Oncologist</i> , 2016, 21, 795-803.	1.9	42
84	FLCRM: Functional Linear Cox Regression Model. <i>Biometrics</i> , 2018, 74, 109-117.	0.8	42
85	Using the EM-algorithm for survival data with incomplete categorical covariates. <i>Lifetime Data Analysis</i> , 1996, 2, 5-14.	0.4	41
86	A new joint model for longitudinal and survival data with a cure fraction. <i>Journal of Multivariate Analysis</i> , 2004, 91, 18-34.	0.5	41
87	Abasic sites preferentially form at regions undergoing DNA replication. <i>FASEB Journal</i> , 2010, 24, 3674-3680.	0.2	41
88	Timeless functions independently of the Tim-Tipin complex to promote sister chromatid cohesion in normal human fibroblasts. <i>Cell Cycle</i> , 2011, 10, 1618-1624.	1.3	41
89	<i>In vivo</i> assessment of the metabolic activity of CYP2D6 diplotypes and alleles. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1122-1130.	1.1	40
90	The large sample distribution of the weighted log rank statistic under general local alternatives. , 1997, 3, 5-12.		39

#	ARTICLE	IF	CITATIONS
91	Incidence of Post Transplant Myelodysplasia/Acute Leukemia in Non-Hodgkin's Lymphoma Patients Compared with Hodgkin's Disease Patients Undergoing Autologous Transplantation Following Cyclophosphamide, Carmustine, and Etoposide (CBV). <i>Leukemia and Lymphoma</i> , 2001, 40, 499-509.	0.6	39
92	Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method. <i>Statistics in Medicine</i> , 2001, 20, 867-882.	0.8	39
93	A Statistical Analysis of Brain Morphology Using Wild Bootstrapping. <i>IEEE Transactions on Medical Imaging</i> , 2007, 26, 954-966.	5.4	39
94	Incomplete Data in Generalized Linear Models. , 0, .		39
95	Bayesian influence analysis: a geometric approach. <i>Biometrika</i> , 2011, 98, 307-323.	1.3	38
96	Bayesian Lasso for Semiparametric Structural Equation Models. <i>Biometrics</i> , 2012, 68, 567-577.	0.8	38
97	JMFit: A SAS Macro for Joint Models of Longitudinal and Survival Data. <i>Journal of Statistical Software</i> , 2016, 71, .	1.8	38
98	A generalized linear mixed model for longitudinal binary data with a marginal logit link function. <i>Annals of Applied Statistics</i> , 2011, 5, 449-467.	0.5	37
99	Variable Selection in Regression Mixture Modeling for the Discovery of Gene Regulatory Networks. <i>Journal of the American Statistical Association</i> , 2007, 102, 867-880.	1.8	36
100	Consumption of trans-Fatty Acid and Its Association with Colorectal Adenomas. <i>American Journal of Epidemiology</i> , 2008, 168, 289-297.	1.6	36
101	A Community-Based Multicenter Trial of Pharmacokinetically Guided 5-Fluorouracil Dosing for Personalized Colorectal Cancer Therapy. <i>Oncologist</i> , 2014, 19, 959-965.	1.9	36
102	Prior elicitation for model selection and estimation in generalized linear mixed models. <i>Journal of Statistical Planning and Inference</i> , 2003, 111, 57-76.	0.4	35
103	Bayesian Analysis for Generalized Linear Models with Nonignorably Missing Covariates. <i>Biometrics</i> , 2005, 61, 767-780.	0.8	35
104	Properties and Implementation of Jeffreys's Prior in Binomial Regression Models. <i>Journal of the American Statistical Association</i> , 2008, 103, 1659-1664.	1.8	35
105	Theory and inference for regression models with missing responses and covariates. <i>Journal of Multivariate Analysis</i> , 2008, 99, 1302-1331.	0.5	34
106	trans-Fatty acid consumption and its association with distal colorectal cancer in the North Carolina Colon Cancer Study II. <i>Cancer Causes and Control</i> , 2010, 21, 171-180.	0.8	34
107	Non-ignorable missing covariates in generalized linear models. , 1999, 18, 2435-2448.		33
108	Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma. <i>Melanoma Research</i> , 2003, 13, 619-626.	0.6	33

#	ARTICLE	IF	CITATIONS
109	A General Class of Bayesian Survival Models with Zero and Nonzero Cure Fractions. <i>Biometrics</i> , 2005, 61, 403-412.	0.8	33
110	Semiparametric Models for Missing Covariate and Response Data in Regression Models. <i>Biometrics</i> , 2006, 62, 177-184.	0.8	33
111	Bayesian variable selection and computation for generalized linear models with conjugate priors. <i>Bayesian Analysis</i> , 2008, 3, 585-614.	1.6	33
112	Gamma frailty transformation models for multivariate survival times. <i>Biometrika</i> , 2009, 96, 277-291.	1.3	33
113	Bayesian Meta-Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. <i>Biometrics</i> , 2012, 68, 578-586.	0.8	33
114	Interferon alfa-2a for melanoma metastases. <i>Lancet, The</i> , 2002, 359, 978-979.	6.3	32
115	Maximum likelihood estimation in generalized linear models with multiple covariates subject to detection limits. <i>Statistics in Medicine</i> , 2011, 30, 2551-2561.	0.8	32
116	Assessing model fit in joint models of longitudinal and survival data with applications to cancer clinical trials. <i>Statistics in Medicine</i> , 2014, 33, 4715-4733.	0.8	32
117	VARIABLE SELECTION FOR REGRESSION MODELS WITH MISSING DATA. <i>Statistica Sinica</i> , 2010, 20, 149-165.	0.2	32
118	On Bayesian Analysis of Generalized Linear Models Using Jeffreys's Prior. , 0, .		29
119	The Bayesian covariance lasso. <i>Statistics and Its Interface</i> , 2013, 6, 243-259.	0.2	29
120	Longitudinal Design for Phase I Clinical Trials Using the Continual Reassessment Method. <i>Contemporary Clinical Trials</i> , 2000, 21, 574-588.	2.0	28
121	Bayesian Model Assessment in Joint Modeling of Longitudinal and Survival Data With Applications to Cancer Clinical Trials. <i>Journal of Computational and Graphical Statistics</i> , 2017, 26, 121-133.	0.9	28
122	Bayesian adaptive basket trial design using model averaging. <i>Biostatistics</i> , 2021, 22, 19-34.	0.9	27
123	Bayesian cure rate models for malignant melanoma: a case-study of Eastern Cooperative Oncology Group trial E1690. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2002, 51, 135-150.	0.5	26
124	A Class of Bayesian Shared Gamma Frailty Models with Multivariate Failure Time Data. <i>Biometrics</i> , 2005, 61, 208-216.	0.8	26
125	Current Methods for Recurrent Events Data With Dependent Termination. <i>Journal of the American Statistical Association</i> , 2008, 103, 866-878.	1.8	26
126	Joint modeling of longitudinal and survival data with missing and left-censored time-varying covariates. <i>Statistics in Medicine</i> , 2014, 33, 4560-4576.	0.8	26



#	ARTICLE	IF	CITATIONS
127	Maximum likelihood inference for the Cox regression model with applications to missing covariates. <i>Journal of Multivariate Analysis</i> , 2009, 100, 2018-2030.	0.5	25
128	Estimating treatment effects with treatment switching via semicompeting risks models: an application to a colorectal cancer study. <i>Biometrika</i> , 2012, 99, 167-184.	1.3	25
129	Bayesian Influence Measures for Joint Models for Longitudinal and Survival Data. <i>Biometrics</i> , 2012, 68, 954-964.	0.8	25
130	Non-ignorable missing covariate data in survival analysis: a case-study of an International Breast Cancer Study Group trial. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2004, 53, 293-310.	0.5	24
131	BFLCRM: A Bayesian functional linear Cox regression model for predicting time to conversion to Alzheimer's disease. <i>Annals of Applied Statistics</i> , 2015, 9, 2153-2178.	0.5	24
132	A Bayesian hierarchical model for network meta-analysis of multiple diagnostic tests. <i>Biostatistics</i> , 2018, 19, 87-102.	0.9	24
133	MRLocus: Identifying causal genes mediating a trait through Bayesian estimation of allelic heterogeneity. <i>PLoS Genetics</i> , 2021, 17, e1009455.	1.5	24
134	Posterior propriety and computation for the Cox regression model with applications to missing covariates. <i>Biometrika</i> , 2006, 93, 791-807.	1.3	23
135	Variable Selection in the Cox Regression Model with Covariates Missing at Random. <i>Biometrics</i> , 2010, 66, 97-104.	0.8	23
136	Perturbation and scaled Cook's distance. <i>Annals of Statistics</i> , 2012, 40, 785-811.	1.4	23
137	Mapping the Genetic Variation of Regional Brain Volumes as Explained by All Common SNPs from the ADNI Study. <i>PLoS ONE</i> , 2013, 8, e71723.	1.1	23
138	A Weighted Estimating Equation for Missing Covariate Data with Properties Similar to Maximum Likelihood. , 0, .		23
139	Bias in Estimating Association Parameters for Longitudinal Binary Responses with Dropouts. <i>Biometrics</i> , 2001, 57, 15-21.	0.8	22
140	Bayesian methods for missing covariates in cure rate models. <i>Lifetime Data Analysis</i> , 2002, 8, 117-146.	0.4	22
141	A Predictive Approach to the Analysis of Designed Experiments. , 0, .		22
142	Use of Historical Controls in Time-Adjusted Trend Tests for Carcinogenicity. <i>Biometrics</i> , 1996, 52, 1478.	0.8	21
143	On Bayesian inference for proportional hazards models using noninformative priors. <i>Lifetime Data Analysis</i> , 2000, 6, 331-341.	0.4	21
144	Local Influence for Generalized Linear Models with Missing Covariates. <i>Biometrics</i> , 2009, 65, 1164-1174.	0.8	21

#	ARTICLE	IF	CITATIONS
145	A practical Bayesian adaptive design incorporating data from historical controls. <i>Statistics in Medicine</i> , 2018, 37, 4054-4070.	0.8	21
146	Pseudo-likelihood methods for longitudinal binary data with non-ignorable missing responses and covariates. <i>Statistics in Medicine</i> , 2006, 25, 2784-2796.	0.8	20
147	Loss of lung function among sheet metal workers: Ten-year study. , 1997, 32, 460-466.		19
148	Propriety of the Posterior Distribution and Existence of the MLE for Regression Models With Covariates Missing at Random. <i>Journal of the American Statistical Association</i> , 2004, 99, 421-438.	1.8	19
149	Time course investigation of PPAR $\alpha$ - and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression. <i>Toxicology and Applied Pharmacology</i> , 2007, 225, 267-277.	1.3	19
150	Separation of intra-S checkpoint protein contributions to DNA replication fork protection and genomic stability in normal human fibroblasts. <i>Cell Cycle</i> , 2013, 12, 332-345.	1.3	19
151	Bayesian longitudinal low-rank regression models for imaging genetic data from longitudinal studies. <i>NeuroImage</i> , 2017, 149, 305-322.	2.1	19
152	A Semiparametric Mixture Model for Analyzing Clustered Competing Risks Data. <i>Biometrics</i> , 2005, 61, 729-737.	0.8	18
153	Estimation in regression models for longitudinal binary data with outcome-dependent follow-up. <i>Biostatistics</i> , 2005, 7, 469-485.	0.9	18
154	Bayesian probability of success for clinical trials using historical data. <i>Statistics in Medicine</i> , 2015, 34, 249-264.	0.8	18
155	ICeD-T Provides Accurate Estimates of Immune Cell Abundance in Tumor Samples by Allowing for Aberrant Gene Expression Patterns. <i>Journal of the American Statistical Association</i> , 2020, 115, 1055-1065.	1.8	18
156	A weighted estimating equation for linear regression with missing covariate data. <i>Statistics in Medicine</i> , 2002, 21, 2421-2436.	0.8	17
157	Bayesian Error-in-Variable Survival Model for the Analysis of GeneChip Arrays. <i>Biometrics</i> , 2005, 61, 488-497.	0.8	17
158	Wavelet Thresholding with Bayesian False Discovery Rate Control. <i>Biometrics</i> , 2005, 61, 25-35.	0.8	16
159	Inference for a Class of Transformed Hazards Models. <i>Journal of the American Statistical Association</i> , 2005, 100, 1000-1008.	1.8	16
160	Bayesian design of superiority clinical trials for recurrent events data with applications to bleeding and transfusion events in myelodysplastic syndrome. <i>Biometrics</i> , 2014, 70, 1003-1013.	0.8	16
161	Bayesian gamma frailty models for survival data with semi-competing risks and treatment switching. <i>Lifetime Data Analysis</i> , 2014, 20, 76-105.	0.4	16
162	Mechanisms of chromosomal instability in melanoma. <i>Environmental and Molecular Mutagenesis</i> , 2014, 55, 457-471.	0.9	16

#	ARTICLE	IF	CITATIONS
163	Bayesian variable selection for the Cox regression model with missing covariates. <i>Lifetime Data Analysis</i> , 2008, 14, 496-520.	0.4	15
164	Associations Between Trans Fatty Acid Consumption and Colon Cancer Among Whites and African Americans in the North Carolina Colon Cancer Study I. <i>Nutrition and Cancer</i> , 2009, 61, 427-436.	0.9	15
165	Projection Regression Models for Multivariate Imaging Phenotype. <i>Genetic Epidemiology</i> , 2012, 36, 631-641.	0.6	15
166	Likelihood Methods for Incomplete Longitudinal Binary Responses with Incomplete Categorical Covariates. <i>Biometrics</i> , 1999, 55, 214-223.	0.8	14
167	Proximity Model for Expression Quantitative Trait Loci (eQTL) Detection. <i>Biometrics</i> , 2007, 63, 1108-1116.	0.8	14
168	Diagnostic Measures for Generalized Linear Models with Missing Covariates. <i>Scandinavian Journal of Statistics</i> , 2009, 36, 686-712.	0.9	14
169	Development of DNA Damage Response Signaling Biomarkers using Automated, Quantitative Image Analysis. <i>Journal of Histochemistry and Cytochemistry</i> , 2014, 62, 185-196.	1.3	14
170	Maximum likelihood estimation in random effects cure rate models with nonignorable missing covariates. <i>Biostatistics</i> , 2002, 3, 387-405.	0.9	13
171	Bayesian Methods for a Three-State Model for Rodent Carcinogenicity Studies. <i>Biometrics</i> , 2002, 58, 906-916.	0.8	13
172	Identification of Differentially Expressed Genes in High-Density Oligonucleotide Arrays Accounting for the Quantification Limits of the Technology. <i>Biometrics</i> , 2003, 59, 542-554.	0.8	13
173	Estimation and inference for case-control studies with multiple non-gold standard exposure assessments: with an occupational health application. <i>Biostatistics</i> , 2009, 10, 591-602.	0.9	13
174	Bayesian methods in clinical trials: a Bayesian analysis of ECOG trials E1684 and E1690. <i>BMC Medical Research Methodology</i> , 2012, 12, 183.	1.4	13
175	A prognostic signature of G <sub>2</sub> M checkpoint function in melanoma cell lines. <i>Cell Cycle</i> , 2013, 12, 1071-1082.	1.3	13
176	Bayesian sequential meta-analysis design in evaluating cardiovascular risk in a new antidiabetic drug development program. <i>Statistics in Medicine</i> , 2014, 33, 1600-1618.	0.8	13
177	An Information Matrix Prior for Bayesian Analysis in Generalized Linear Models with High Dimensional Data. <i>Statistica Sinica</i> , 2009, 19, 1641-1663.	0.2	13
178	Frailty Models with Missing Covariates. <i>Biometrics</i> , 2002, 58, 98-109.	0.8	12
179	Bayesian local influence for survival models. <i>Lifetime Data Analysis</i> , 2011, 17, 43-70.	0.4	12
180	TPRM: Tensor partition regression models with applications in imaging biomarker detection. <i>Annals of Applied Statistics</i> , 2018, 12, 1422-1450.	0.5	12

#	ARTICLE	IF	CITATIONS
181	A temporal hidden Markov regression model for the analysis of gene regulatory networks. <i>Biostatistics</i> , 2006, 8, 805-820.	0.9	11
182	On the estimation of disease prevalence by latent class models for screening studies using two screening tests with categorical disease status verified in test positives only. <i>Statistics in Medicine</i> , 2010, 29, 1206-1218.	0.8	11
183	Flexible Stopping Boundaries When Changing Primary Endpoints After Unblinded Interim Analyses. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 817-833.	0.4	11
184	Control-based imputation for sensitivity analyses in informative censoring for recurrent event data. <i>Pharmaceutical Statistics</i> , 2017, 16, 424-432.	0.7	11
185	Modeling Between-Study Heterogeneity for Improved Replicability in Gene Signature Selection and Clinical Prediction. <i>Journal of the American Statistical Association</i> , 2020, 115, 1125-1138.	1.8	11
186	Bayesian predictive simultaneous variable and transformation selection in the linear model. <i>Computational Statistics and Data Analysis</i> , 1998, 28, 87-103.	0.7	10
187	Bayesian Predictive Inference for Time Series Count Data. <i>Biometrics</i> , 2000, 56, 678-685.	0.8	10
188	A Note on the Validity of Statistical Bootstrapping for Estimating the Uncertainty of Tensor Parameters in Diffusion Tensor Images. <i>IEEE Transactions on Medical Imaging</i> , 2008, 27, 1506-1514.	5.4	10
189	Rejoinder on: Missing data methods in longitudinal studies: a review. <i>Test</i> , 2009, 18, 68-75.	0.7	10
190	A Bayesian Hidden Markov Model for Motif Discovery Through Joint Modeling of Genomic Sequence and ChIP-Seq Data. <i>Biometrics</i> , 2009, 65, 1087-1095.	0.8	10
191	A Bayesian proportional hazards regression model with non-ignorably missing time-varying covariates. <i>Statistics in Medicine</i> , 2010, 29, 3017-3029.	0.8	10
192	Bayesian inference for multivariate meta-analysis Box-Cox transformation models for individual patient data with applications to evaluation of cholesterol-lowering drugs. <i>Statistics in Medicine</i> , 2013, 32, 3972-3990.	0.8	10
193	Cyclobutane Pyrimidine Dimer Density as a Predictive Biomarker of the Biological Effects of Ultraviolet Radiation in Normal Human Fibroblast. <i>Photochemistry and Photobiology</i> , 2014, 90, 145-154.	1.3	10
194	SPReM: Sparse Projection Regression Model For High-Dimensional Linear Regression. <i>Journal of the American Statistical Association</i> , 2015, 110, 289-302.	1.8	10
195	Effect of grass sublingual tablet immunotherapy is similar in children and adults: A Bayesian approach to design pediatric sublingual immunotherapy trials. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1744-1749.	1.5	10
196	Using Historical Controls to Adjust for Covariates in Trend Tests for Binary Data. , 0, .		10
197	A note on the relationships between multiple imputation, maximum likelihood and fully Bayesian methods for missing responses in linear regression models. <i>Statistics and Its Interface</i> , 2013, 6, 315-324.	0.2	10
198	Bayesian Case Influence Measures for Statistical Models With Missing Data. <i>Journal of Computational and Graphical Statistics</i> , 2012, 21, 253-271.	0.9	9

#	ARTICLE	IF	CITATIONS
199	Estimating time-varying effects for overdispersed recurrent events data with treatment switching. <i>Biometrika</i> , 2013, 100, 339-354.	1.3	9
200	Multivariate Recurrent Events in the Presence of Multivariate Informative Censoring with Applications to Bleeding and Transfusion Events in Myelodysplastic Syndrome. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 429-442.	0.4	9
201	The Use of Bayesian Hierarchical Models for Adaptive Randomization in Biomarker-Driven Phase II Studies. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 66-88.	0.4	9
202	DNA Damage Checkpoint Responses in the S Phase of Synchronized Diploid Human Fibroblasts. <i>Photochemistry and Photobiology</i> , 2015, 91, 109-116.	1.3	9
203	Bayesian Inference for Multivariate Meta-Regression With a Partially Observed Within-Study Sample Covariance Matrix. <i>Journal of the American Statistical Association</i> , 2015, 110, 528-544.	1.8	9
204	Diagnostic measures for the Cox regression model with missing covariates. <i>Biometrika</i> , 2015, 102, 907-923.	1.3	9
205	On inference of control-based imputation for analysis of repeated binary outcomes with missing data. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 358-372.	0.4	9
206	Bayesian Sensitivity Analysis of a Nonlinear Dynamic Factor Analysis Model with Nonparametric Prior and Possible Nonignorable Missingness. <i>Psychometrika</i> , 2017, 82, 875-903.	1.2	9
207	A marginal estimate for the overall treatment effect on a survival outcome within the joint modeling framework. <i>Statistics in Medicine</i> , 2020, 39, 4120-4132.	0.8	9
208	Default Bayes factors for generalized linear models. <i>Journal of Statistical Planning and Inference</i> , 2000, 87, 301-315.	0.4	8
209	Sieve Maximum Likelihood Estimation for Regression Models With Covariates Missing at Random. <i>Journal of the American Statistical Association</i> , 2007, 102, 1309-1317.	1.8	8
210	Biomarker threshold adaptive designs for survival endpoints. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 1038-1054.	0.4	8
211	Bayesian design of a survival trial with a cured fraction using historical data. <i>Statistics in Medicine</i> , 2018, 37, 3814-3831.	0.8	8
212	Joint modelling of longitudinal and survival data in the presence of competing risks with applications to prostate cancer data. <i>Statistical Modelling</i> , 2021, 21, 72-94.	0.5	8
213	Bayesian sensitivity analysis of statistical models with missing data. <i>Statistica Sinica</i> , 2014, 24, 871-896.	0.2	8
214	Group sequential designs for cure rate models with early stopping in favour of the null hypothesis. <i>Statistics in Medicine</i> , 2000, 19, 3023-3035.	0.8	7
215	Two-stage empirical likelihood for longitudinal neuroimaging data. <i>Annals of Applied Statistics</i> , 2011, 5, 1132-1158.	0.5	7
216	Sample Size Determination in Shared Frailty Models for Multivariate Time-to-Event Data. <i>Journal of Biopharmaceutical Statistics</i> , 2014, 24, 908-923.	0.4	7

#	ARTICLE	IF	CITATIONS
217	On the normalized power prior. <i>Statistics in Medicine</i> , 2021, 40, 5251-5275.	0.8	7
218	On Properties of Predictive Priors in Linear Models. <i>American Statistician</i> , 1997, 51, 333-337.	0.9	6
219	Incomplete covariates in the Cox model with applications to biological marker data. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 467-484.	0.5	6
220	Bayesian Spatial Transformation Models with Applications in Neuroimaging Data. <i>Biometrics</i> , 2013, 69, 1074-1083.	0.8	6
221	Some Statistical Strategies for DAE-seq Data Analysis: Variable Selection and Modeling Dependencies Among Observations. <i>Journal of the American Statistical Association</i> , 2014, 109, 78-94.	1.8	6
222	Functional-Mixed Effects Models for Candidate Genetic Mapping in Imaging Genetic Studies. <i>Genetic Epidemiology</i> , 2014, 38, 680-691.	0.6	6
223	Responses to discussants of "Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group". <i>Statistics in Medicine</i> , 2015, 34, 2202-2203.	0.8	6
224	Quantifying the average of the time-varying hazard ratio via a class of transformations. <i>Lifetime Data Analysis</i> , 2015, 21, 259-279.	0.4	6
225	Hard thresholding regression. <i>Scandinavian Journal of Statistics</i> , 2019, 46, 314-328.	0.9	6
226	Model-based feature selection and clustering of RNA-seq data for unsupervised subtype discovery. <i>Annals of Applied Statistics</i> , 2021, 15, 481-508.	0.5	6
227	Protective estimator for linear regression with nonignorably missing Gaussian outcomes. <i>Statistical Modelling</i> , 2004, 4, 3-17.	0.5	5
228	Bayesian Hierarchical Modeling for Time Course Microarray Experiments. <i>Biometrics</i> , 2007, 63, 496-504.	0.8	5
229	A new class of mixture models for differential gene expression in DNA microarray data. <i>Journal of Statistical Planning and Inference</i> , 2008, 138, 387-404.	0.4	5
230	A weighted combination of pseudo-likelihood estimators for longitudinal binary data subject to non-ignorable non-monotone missingness. <i>Statistics in Medicine</i> , 2010, 29, 1511-1521.	0.8	5
231	Intrinsic Regression Models for Medial Representation of Subcortical Structures. <i>Journal of the American Statistical Association</i> , 2012, 107, 12-23.	1.8	5
232	Change-point models to estimate the limit of detection. <i>Statistics in Medicine</i> , 2013, 32, 4995-5007.	0.8	5
233	Hypothesis testing for two-stage designs with over or under enrollment. <i>Statistics in Medicine</i> , 2015, 34, 2417-2426.	0.8	5
234	MILFM: Multiple Index Latent Factor Model Based on High-Dimensional Features. <i>Biometrics</i> , 2018, 74, 834-844.	0.8	5

#	ARTICLE	IF	CITATIONS
235	Semiparametric regression analysis for composite endpoints subject to componentwise censoring. <i>Biometrika</i> , 2018, 105, 403-418.	1.3	5
236	Global identifiability of latent class models with applications to diagnostic test accuracy studies: A GrÅbner basis approach. <i>Biometrics</i> , 2020, 76, 98-108.	0.8	5
237	LCN: a random graph mixture model for community detection in functional brain networks. <i>Statistics and Its Interface</i> , 2017, 10, 369-378.	0.2	5
238	A Bayesian Hierarchical Model for the Analysis of Affymetrix Arrays. <i>Annals of the New York Academy of Sciences</i> , 2004, 1020, 41-48.	1.8	4
239	A Bivariate Pseudolikelihood for Incomplete Longitudinal Binary Data with Nonignorable Nonmonotone Missingness. <i>Biometrics</i> , 2011, 67, 1119-1126.	0.8	4
240	Partial least squares for functional joint models with applications to the Alzheimer's disease neuroimaging initiative study. <i>Biometrics</i> , 2020, 76, 1109-1119.	0.8	4
241	Functional Linear Regression Model for Nonignorable Missing Scalar Responses. <i>Statistica Sinica</i> , 2018, 28, 1867-1886.	0.2	4
242	Use and Abuse of Statistics in Evidence-Based Medicine. <i>Journal of Clinical Oncology</i> , 2002, 20, 4122-4124.	0.8	3
243	Meta-analysis methods and models with applications in evaluation of cholesterol-lowering drugs. <i>Statistics in Medicine</i> , 2012, 31, 3597-3616.	0.8	3
244	Bayesian modeling and inference for clinical trials with partial retrieved data following dropout. <i>Statistics in Medicine</i> , 2013, 32, 4180-4195.	0.8	3
245	Is activation of the intra-S checkpoint in human fibroblasts an important factor in protection against UV-induced mutagenesis?. <i>Cell Cycle</i> , 2013, 12, 3555-3563.	1.3	3
246	Statistical design of noninferiority multiple region clinical trials to assess global and consistent treatment effects. <i>Journal of Biopharmaceutical Statistics</i> , 2017, 27, 933-944.	0.4	3
247	Modeling event count data in the presence of informative dropout with application to bleeding and transfusion events in myelodysplastic syndrome. <i>Statistics in Medicine</i> , 2017, 36, 3475-3494.	0.8	3
248	Controlling false discovery proportion in identification of drug-related adverse events from multiple system organ classes. <i>Statistics in Medicine</i> , 2019, 38, 4378-4389.	0.8	3
249	A new Bayesian joint model for longitudinal count data with many zeros, intermittent missingness, and dropout with applications to HIV prevention trials. <i>Statistics in Medicine</i> , 2019, 38, 5565-5586.	0.8	3
250	Efficient Methods for Signal Detection From Correlated Adverse Events in Clinical Trials. <i>Biometrics</i> , 2019, 75, 1000-1008.	0.8	3
251	Bayesian multivariate skew meta-regression models for individual patient data. <i>Statistical Methods in Medical Research</i> , 2019, 28, 3415-3436.	0.7	3
252	Bayesian inference for network meta-regression using multivariate random effects with applications to cholesterol lowering drugs. <i>Biostatistics</i> , 2019, 20, 499-516.	0.9	3

#	ARTICLE	IF	CITATIONS
253	Bayesian design of clinical trials using joint models for longitudinal and time-to-event data. <i>Biostatistics</i> , 2022, 23, 591-608.	0.9	3
254	Network meta-regression for ordinal outcomes: Applications in comparing Crohn's disease treatments. <i>Statistics in Medicine</i> , 2020, 39, 1846-1870.	0.8	3
255	A hierarchical testing approach for detecting safety signals in clinical trials. <i>Statistics in Medicine</i> , 2020, 39, 1541-1557.	0.8	3
256	Weighted functional linear Cox regression model. <i>Statistical Methods in Medical Research</i> , 2021, 30, 1917-1931.	0.7	3
257	Bayesian case-deletion model complexity and information criterion. <i>Statistics and Its Interface</i> , 2014, 7, 531-542.	0.2	3
258	Bayesian Modeling and Inference for Nonignorably Missing Longitudinal Binary Response Data with Applications to HIV Prevention Trials. <i>Statistica Sinica</i> , 2018, 28, 1929-1963.	0.2	3
259	Bayesian multivariate probability of success using historical data with type I error rate control. <i>Biostatistics</i> , 2022, 24, 17-31.	0.9	3
260	Comment: Incomplete Data in Clinical Studies: Analysis, Sensitivity, and Sensitivity Analysis. <i>Drug Information Journal</i> , 2009, 43, 431-432.	0.5	2
261	InSilico Construction of a Protein Interaction Landscape for Nucleotide Excision Repair. <i>Cell Biochemistry and Biophysics</i> , 2009, 53, 101-114.	0.9	2
262	A Semiparametric Bayesian Approach for Estimating the Gene Expression Distribution. <i>Journal of Biopharmaceutical Statistics</i> , 2010, 20, 267-280.	0.4	2
263	Bayesian Transformation Models for Multivariate Survival Data. <i>Scandinavian Journal of Statistics</i> , 2014, 41, 187-199.	0.9	2
264	Assessment of Fit in Longitudinal Data for Joint Models with Applications to Cancer Clinical Trials. <i>ICSA Book Series in Statistics</i> , 2015, , 347-365.	0.0	2
265	A statistical model to assess (allele-specific) associations between gene expression and epigenetic features using sequencing data. <i>Annals of Applied Statistics</i> , 2016, 10, 2254-2273.	0.5	2
266	Semiparametric Frailty Models for Zero-Inflated Event Count Data in the Presence of Informative Dropout. <i>Biometrics</i> , 2019, 75, 1168-1178.	0.8	2
267	Quantifying time-varying cause-specific hazard and subdistribution hazard ratios with competing risks data. <i>Clinical Trials</i> , 2019, 16, 363-374.	0.7	2
268	Bayesian design of biosimilars clinical programs involving multiple therapeutic indications. <i>Biometrics</i> , 2020, 76, 630-642.	0.8	2
269	Joint analysis of single-cell and bulk tissue sequencing data to infer intratumor heterogeneity. <i>Biometrics</i> , 2020, 76, 983-994.	0.8	2
270	Using missing data methods in genetic studies with missing mutation status. , 1999, 18, 473-485.		1



#	ARTICLE	IF	CITATIONS
271	Assessing Similarity to Existing Drugs to Decide Whether to Continue Drug Development. <i>Statistics in Biopharmaceutical Research</i> , 2012, 4, 293-300.	0.6	1
272	Assessing temporal agreement between central and local progression-free survival times. <i>Statistics in Medicine</i> , 2015, 34, 844-858.	0.8	1
273	A Counterfactual P-Value Approach for Benefit-Risk Assessment in Clinical Trials. <i>Journal of Biopharmaceutical Statistics</i> , 2015, 25, 508-524.	0.4	1
274	Homology cluster differential expression analysis for interspecies mRNA-Seq experiments. <i>Statistical Applications in Genetics and Molecular Biology</i> , 2015, 14, 507-16.	0.2	1
275	SR-HARDI: Spatially Regularizing High Angular Resolution Diffusion Imaging. <i>Journal of Computational and Graphical Statistics</i> , 2016, 25, 1195-1211.	0.9	1
276	Pattern mixture models for clinical validation of biomarkers in the presence of missing data. <i>Statistics in Medicine</i> , 2017, 36, 2994-3004.	0.8	1
277	Bayesian clinical trial design using Markov models with applications to autoimmune disease. <i>Contemporary Clinical Trials</i> , 2017, 63, 73-83.	0.8	1
278	Estimating Treatment Effects for Recurrent Events in the Presence of Rescue Medications: An Application to the Immune Thrombocytopenia Study. <i>Statistics in Biosciences</i> , 2018, 10, 473-489.	0.6	1
279	Efficient Multiple Imputation for Sensitivity Analysis of Recurrent Events Data With Informative Censoring. <i>Statistics in Biopharmaceutical Research</i> , 2020, , 1-9.	0.6	1
280	Bayesian network meta-regression hierarchical models using heavy-tailed multivariate random effects with covariate-dependent variances. <i>Statistics in Medicine</i> , 2021, 40, 3582-3603.	0.8	1
281	Bayesian Flexible Hierarchical Skew Heavy-Tailed Multivariate Meta Regression Models for Individual Patient Data with Applications. <i>Statistics and Its Interface</i> , 2020, 13, 485-500.	0.2	1
282	Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 326-33.	2.0	1
283	Rejoinder: Bayesian local influence for survival models. <i>Lifetime Data Analysis</i> , 2011, 17, 76-79.	0.4	0
284	Reply to Comments. <i>Statistics in Medicine</i> , 2016, 35, 1560-1560.	0.8	0
285	Improved Detection of Epigenomic Marks with Mixed-Effects Hidden Markov Models. <i>Biometrics</i> , 2019, 75, 1401-1413.	0.8	0
286	A Powerful Global Test Statistic for Functional Statistical Inference. <i>Proceedings of the AAAI Conference on Artificial Intelligence</i> , 2019, 33, 5765-5772.	3.6	0
287	Inferring latent heterogeneity using many feature variables supervised by survival outcome. <i>Statistics in Medicine</i> , 2021, 40, 3181-3195.	0.8	0
288	A Power Prior Approach for Leveraging External Longitudinal and Competing Risks Survival Data Within the Joint Modeling Framework. <i>Statistics in Biosciences</i> , 0, , 1.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Penalized logistic regression using functional connectivity as covariates with an application to mild cognitive impairment. Communications for Statistical Applications and Methods, 2020, 27, 603-624.	0.1	0
290	BayesCTDesign: An R Package for Bayesian Trial Design Using Historical Control Data. Journal of Statistical Software, 2021, 100, .	1.8	0
291	A hierarchical prior for generalized linear models based on predictions for the mean response. Biostatistics, 0, , .	0.9	0
292	Bayesian design of clinical trials using joint models for recurrent and terminating events. Biostatistics, 0, , .	0.9	0